Bacteriophage therapy: history and future prospects

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Future Virology

• Publication date

  2015-04-27

• Fields of study

  Biology, Medicine, History

• Identifiers
  DOI 10.2217/FVL.15.3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Bacteriophage and Its Behavior

  2017cited by this paper
• Phage Therapy: Eco-Physiological Pharmacology

  2014influential reference
• Persisters and beyond: Mechanisms of phenotypic drug resistance and drug tolerance in bacteria

  2014cited by this paper
• Phage therapy and phage control: to be revisited urgently!!

  2014influential reference
• Phage therapy gets revitalized

  2014cited by this paper
• Phage Neutralization by Sera of Patients Receiving Phage Therapy

  2014cited by this paper
• Experimental phage therapy of burn wound infection: difficult first steps.

  2014cited by this paper
• Taking Bacteriophage Therapy Seriously: A Moral Argument

  2014cited by this paper
• Bacteriophage: Therapeutic Uses

  2014cited by this paper
• Phage therapy in the food industry.

  2014cited by this paper
• Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection.

  2013cited by this paper
• Respiratory viral testing

  2013cited by this paper
• Paving a regulatory pathway for phage therapy

  2013cited by this paper
• Importance of prophages to evolution and virulence of bacterial pathogens

  2013cited by this paper
• A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens

  2013cited by this paper
• Fixing a broken drug development process

  2013cited by this paper
• What are the limitations on the wider therapeutic use of phage?

  2013cited by this paper
• The strange history of phage therapy

  2012cited by this paper
• Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine

  2012influential reference
• Next generation sequencing technologies and the changing landscape of phage genomics

  2012cited by this paper
• Considerations for using bacteriophages for plant disease control

  2012cited by this paper
• Bacteria-virus coevolution.

  2012cited by this paper
• The role of regulated clinical trials in the development of bacteriophage therapeutics

  2012cited by this paper
• Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh.

  2012cited by this paper
• Gut microbiota disturbance during antibiotic therapy: a multi-omic approach

  2012cited by this paper
• Bacteriophages and Their Role in Food Safety

  2012cited by this paper
• Clinical aspects of phage therapy.

  2012cited by this paper
• Selection and Characterization of a Candidate Therapeutic Bacteriophage That Lyses the Escherichia coli O104:H4 Strain from the 2011 Outbreak in Germany

  2012cited by this paper
• Diseases caused by phages.

  2012cited by this paper
• Tackling antibiotic resistance

  2011cited by this paper
• Development of a broad-host-range phage cocktail for biocontrol

  2011cited by this paper
• Fix the antibiotics pipeline

  2011cited by this paper
• Phage treatment of human infections

  2011cited by this paper
• d’Hérelle. Preparation of Therapeutic Bacteriophages, Appendix 1 from: Le Phénomène de la Guérison dans les maladies infectieuses: Masson et Cie, 1938, Paris—OCLC 5784382

  2011cited by this paper
• Pros and cons of phage therapy

  2011cited by this paper
• In the beginning..2

  2011cited by this paper
• Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy

  2011cited by this paper
• Phage-based biocontrol strategies to reduce foodborne pathogens in foods

  2011cited by this paper
• Assessment of Escherichia coli O157:H7-specific bacteriophages e11/2 and e4/1c in model broth and hide environments.

  2011cited by this paper
• Phage therapy pharmacology: calculating phage dosing.

  2011cited by this paper
• The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?

  2011cited by this paper
• Race against time to develop new antibiotics.

  2011cited by this paper
• Bacteriophage host range and bacterial resistance.

  2010cited by this paper
• Phage therapy in clinical practice: treatment of human infections.

  2010cited by this paper
• Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

  2010cited by this paper
• Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial.

  2010cited by this paper
• Ecological Basis for Rational Phage Therapy

  2010cited by this paper
• Bacteriophage therapy for the treatment of infections.

  2009cited by this paper
• Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence β-lactams)

  2009cited by this paper
• Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

  2009cited by this paper
• A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy

  2009cited by this paper
• Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials

  2009cited by this paper
• Bacteriophage Therapy: Past and Present

  2009cited by this paper
• The role of interactions between phage and bacterial proteins within the infected cell: a diverse and puzzling interactome.

  2009cited by this paper
• The First Use of Penicillin in the United States

  2008cited by this paper
• Multidrug tolerance of biofilms and persister cells.

  2008cited by this paper
• Viruses vs Superbugs: A Solution to the Antibiotic Crisis?

  2007cited by this paper
• European regulatory conundrum of phage therapy.

  2007cited by this paper
• Phage therapy: the western perspective.

  2007cited by this paper
• Biotechnological challenges of phage therapy

  2007cited by this paper
• Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials.

  2006cited by this paper
• Phage therapy: facts and fiction.

  2006cited by this paper
• Viruses vs. superbugs

  2006cited by this paper
• An empirical analysis of the valley of death: Large‐scale R&D project performance in a Japanese diversified company

  2006cited by this paper
• Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy

  2005cited by this paper
• The composition of Ehrlich's salvarsan: resolution of a century-old debate.

  2005cited by this paper
• Bacteriophage Therapy in Humans

  2004cited by this paper
• The prospect for bacteriophage therapy in Western medicine

  2003cited by this paper
• Why is big Pharma getting out of antibacterial drug discovery?

  2003cited by this paper
• The antibody response to bacteriophage is linked to the lymphopenia gene in congenic BioBreeding rats.

  2002cited by this paper
• Regulatory issues for phage‐based clinical products

  2001cited by this paper
• Bacteriophages: biology and history

  2001cited by this paper
• Félix d'Herelle and the origins of molecular biology

  2001cited by this paper
• Phage therapy: The peculiar kinetics of self‐replicating pharmaceuticals

  2000cited by this paper
• Appropriate use of restricted antimicrobial agents in hospitals: the importance of empirical therapy and assisted re-evaluation.

  2000cited by this paper
• Merits, flaws of live virus flu vaccine debated.

  2000cited by this paper
• Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential.

  1997cited by this paper
• The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages.

  1987cited by this paper
• Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986.

  1987cited by this paper
• Factors influencing the survival and multiplication of bacteriophages in calves and in their environment.

  1987cited by this paper
• Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results.

  1983cited by this paper
• Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs.

  1983cited by this paper
• Efficacy of staphylococcal bacteriophage in the treatment of purulent lung and pleural diseases

  1982cited by this paper
• Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics.

  1982cited by this paper
• Persisting bacteriophage infections, lysogeny, and phage conversions.

  1974cited by this paper
• Fate of Bacteriophage Particles Introduced into Mice by Various Routes.∗

  1958cited by this paper
• Staphylococcemia 1931–1940. Five Hundred Patients

  1942cited by this paper
• THE BACTERIOPHAGE: ITS NATURE AND ITS THERAPEUTIC USE

  1941cited by this paper
• ONE HUNDRED PATIENTS WITH STAPHYLOCOCCUS SEPTICEMIA RECEIVING BACTERIOPHAGE SERVICE

  1936cited by this paper
• BACTERIOPHAGE THERAPY: REVIEW OF THE PRINCIPLES AND RESULTS OF THE USE OF BACTERIOPHAGE IN THE TREATMENT OF INFECTIONS

  1934cited by this paper
• STUDIES ON COMMERCIAL BACTERIOPHAGE PRODUCTS

  1933cited by this paper
• Bacteriophage in the treatment and prevention of cholera

  1932cited by this paper
• THE BACTERIOLYSANT THERAPY OF BACILLARY DYSENTERY IN CHILDREN: THERAPEUTIC APPLICATION OF BACTERIOLYSANTS; D'HERELLE'S PHENOMENON

  1922cited by this paper
• AN INVESTIGATION ON THE NATURE OF ULTRA-MICROSCOPIC VIRUSES.

  1915cited by this paper
• Studies on Asiatic Cholera.

  year unknowncited by this paper

• Characterization and complete genome analysis of Klebsiella phage Kp109 with lytic activity against Klebsiella pneumoniae

  2024cites this paper
• Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art

  2024cites this paper
• Bacteriophage applications in aquaculture

  2023cites this paper
• Bacteriophage Therapy Against Antimicrobial Resistant Crisis

  2023cites this paper
• A Century of Clinical Use of Phages: A Literature Review

  2023influential citation
• CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance

  2023cites this paper
• Strategies for lipid-based nanocomposites with potential activity against Mycobacterium tuberculosis: Microbial resistance challenge and drug delivery trends

  2023cites this paper
• Isolation and Characterization of a Lytic Vibriophage OY1 and Its Biocontrol Effects Against Vibrio spp.

  2022cites this paper
• Isolating and sequencing vB_Kpn_3, a lytic bacteriophage against multidrug-resistant Klebsiella pneumoniae.

  2022cites this paper
• Three synthetic biology applications and their paths to impact in Australia: Cane toads, bacteriophages, and biomining microbes

  2022cites this paper
• Article Review: Phage Therapy is a Potential Alternative for Antimicrobial Agents

  2022cites this paper
• Isolation of Lytic Bacteriophages from Sewage Samples against MDR-Klebsiella pneumoniae and MDR-Enterobacter aerogenes: A potential tool for medical purposes

  2021cites this paper
• Alternatives to Conventional Antibiotic Therapy: Potential Therapeutic Strategies of Combating Antimicrobial-Resistance and Biofilm-Related Infections

  2021cites this paper
• Isolation and Characterization of Novel Phages Targeting Xanthomonas oryzae: Culprit of Bacterial Leaf Blight Disease in Rice.

  2021cites this paper
• Investigating the impact of combination phage and antibiotic therapy: a modeling study

  2020cites this paper
• Implications of mixed viral infections on plant disease ecology and evolution.

  2020cites this paper
• Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review.

  2019cites this paper
• Ameliorating the antimicrobial resistance crisis: phage therapy

  2019cites this paper
• Bacteriophage cocktails as an environmentally-friendly approach to prevent Vibrio parahaemolyticus and Vibrio harveyi infections in brine shrimp (Artemia franciscana) production

  2018cites this paper
• Isolation and Characterization of Phages Infecting Streptomyces azureus

  2018cites this paper
• Bacteriophages in the control of pathogenic vibrios

  2018cites this paper
• Print to detect: a rapid and ultrasensitive phage-based dipstick assay for foodborne pathogens

  2018cites this paper
• Bacteriophage ZCKP1: A Potential Treatment for Klebsiella pneumoniae Isolated From Diabetic Foot Patients

  2018cites this paper
• Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria

  2017cites this paper
• Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca

  2017cites this paper
• Modeling the synergistic elimination of bacteria by phage and the innate immune system.

  2017cites this paper
• Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.

  2016cites this paper
• Synergistic elimination of bacteria by phage and the innate immune system

  2016cites this paper
• Novel strategies to combat gram-negative bacterial pathogens using bacteriophage proteins

  2015cites this paper
• Viruses That Can Cure, When Antibiotics Fail...

  2015cites this paper
• Research progress and prevention methods of Litopenaeus vannamei Vibrio disease

  year unknowncites this paper
• BACTERIOPHAGES: A SUITABLE ALTERNATIVE FOR ANTIBIOTICS?

  year unknowncites this paper